OSI
-
Labor L+S AG, Symbiosis form alliance
Labor L+S AG, Bad Bocklet and Symbiosis, the newly created business division of Biopharm GmbH, Heidelberg, announced that they have entered into an exclusive business alliance.
OSI | 16 May 2012
-
Merck receives European approval to expand use of Rebif
Merck announced that the European Commission (EC) has approved extension of the indication of Rebif (interferon beta-1a), its treatment for relapsing forms of multiple sclerosis (MS).
OSI | 02 March 2012
-
Biosimilars provide cost saving to users, industry
Biosimilars provide significant cost saving to both the users and the industry hence the adoption of these drugs are expected to be higher side.
OSI | 24 February 2012
-
Roche reports positive study of Herceptin given by subcutaneous injection
Phase 3 study of a quicker route of administration shows comparable results to intravenous Herceptin.
OSI | 18 October 2011
-
Forest Laboratories and Gedeon Richter announce positive results with investigational antipsychotic agent
Data showed that cariprazine-treated patients with acute manic episodes experienced significant symptom improvement compared to placebo-treated patients.
OSI | 05 October 2011
-
FDA approves Zelboraf for treatment of BRAF mutation-positive metastatic melanoma
Roche announced that the US Food and Drug Administration (FDA) approved Zelboraf (vemurafenib) for the treatment of BRAF V600E mutation-positive, inoperable or metastatic melanoma, as determined by an FDA-approved test. The FDA today also approved th…
OSI | 17 August 2011
-
Bayer to support WHO and Stop TB Partnership in fighting tuberculosis
Bayer HealthCare has agreed to support the World Health Organization (WHO) and the Stop TB Partnership in the fight against multidrug-resistant tuberculosis (MDR-TB) by making 620,000 tablets of the antibiotic moxifloxacin available to WHO. Through t…
OSI | 16 August 2011
-
Biogen Idec, Abbott report positive results from trial of daclizumab HYP
Biogen Idec and Abbott announced positive top-line results from SELECT, a global, registrational phase 2b clinical trial designed to evaluate the investigational compound daclizumab high-yield process (DAC HYP) in people with relapsing-remitting mult…
OSI | 09 August 2011
-
Biogen Idec identify novel approach for treatment of multiple sclerosis
Biogen Idec announced results from a study that suggest that inhibiting death receptor-6 (DR6) function may represent a novel approach in the treatment of multiple sclerosis by blocking autoimmune response while promoting remyelination. Data from in …
OSI | 04 July 2011
-
Biogen Idec identify novel approach for treatment of multiple sclerosis
Biogen Idec announced results from a study that suggest that inhibiting death receptor-6 (DR6) function may represent a novel approach in the treatment of multiple sclerosis by blocking autoimmune response while promoting remyelination. Data from in …
OSI | 01 July 2011
